Recent Updates
Recently added Catalysts

CF 102

Phase 1

Chronic Hepatitis C | Small molecule | Infectious Disease |Can-Fite Biopharma Ltd|Last Updated: Apr 15, 2015

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials1
Total Enrollment32

FDA Designations

No designations recorded

Clinical trial landscape

CF 102 · 1 trial · 1 indication

Phase 1 1
NCT00790673A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1Chronic Hepatitis C
COMPLETED32 Analytics
PHASE1COMPLETED
A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1
Chronic Hepatitis C
NCT0079067332
Unlock trial analytics

Study Endpoints

Primary Endpoints

Adverse Event Profile of Repeated Dosing of CF102
16 weeks
Effect of Viral Load
16 weeks
Pharmacokinetic Behavior of CF102 During Repeated Dosing
16 weeks

Secondary Endpoints

Evaluation of the Relationship Between Biomarkers of Peripheral Blood Mononuclear Cell Adenosine 3 Receptor (A3R) Expression and Clinical Effects
16 weeks
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
1EXPERIMENTALCF102 1 mg qd
2EXPERIMENTALCF102 1 mg bid
3EXPERIMENTALCF102 1 mg bid; 16 weeks
5PLACEBO_COMPARATOR -

Interventions

NameTypeDescription
CF 102DRUGOral capsules
PlaceboDRUGMatching placebo capsules
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 60 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: 1. 18 to 60 years of age 2. Body mass index ≤ 30 kg/m2 3. Either: 1. no evidence of cirrhosis, or liver fibrosis corresponding to Metavir Stages 0 to 31 on a liver biopsy performed within the past 2 years, or 2. a score of F0 or F1 on ActiTest-FibroTest performed within t...

Countries:Israel
Unlock Eligibility Criteria

Frequently asked questions about CF 102

What is CF 102 used for?

CF 102 is an investigational small molecule being studied for chronic Hepatitis C, hepatocellular carcinoma (HCC), and non-alcoholic steatohepatitis (NASH). It is being developed by Can-Fite Biopharma Ltd (CANF) and is currently in Phase 1 clinical development for these indications.

What does CF 102 target?

CF 102 is a small molecule that targets the A3 adenosine receptor, which is involved in the regulation of cell growth and apoptosis. By activating this receptor, CF 102 may inhibit tumor cell proliferation and reduce inflammation, making it a potential treatment for liver diseases and cancers.

Who makes CF 102?

CF 102 is being developed by Can-Fite Biopharma Ltd, a biopharmaceutical company traded on the stock exchange under the ticker symbol CANF. The company is focused on developing small molecule drugs for inflammatory and oncological indications.

What phase is CF 102 in?

CF 102 is currently in Phase 1 clinical development. It has completed Phase 1 and Phase 2 trials for hepatocellular carcinoma, chronic Hepatitis C, and non-alcoholic steatohepatitis, but it is not yet approved by regulatory authorities and remains investigational.

What clinical trials is CF 102 in?

CF 102 has completed several clinical trials, including NCT00790218 for advanced hepatocellular carcinoma, NCT00790673 for chronic Hepatitis C genotype 1, NCT02128958 for hepatocellular carcinoma, and NCT02927314 for non-alcoholic fatty liver disease. These trials have been completed, with no active trials currently ongoing.

Is CF 102 the same as other drugs?

CF 102 is also known as namodenoson, a selective A3 adenosine receptor agonist. It is being investigated for its potential to treat liver diseases and cancers, and it is distinct from other adenosine receptor agonists due to its high selectivity for the A3 subtype.